A/Prof Tim Clay

Medical oncologist from Perth - Australia. Interested in thoracic oncology, breast cancer, GUs, clinical trials, fast cars (Formula 1) and @werderbremen_en

[Neil Stone @DrNeilStone]

My home country Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿

NO cervical cancer cases detected in vaccinated women following HPV immunisation!

None! Zero!

What a stunning achievement !

The HPV vaccine ie a modern medical miracle!

[A/Prof Tim Clay @drtclay]

@RWinayak @montypal

Very impressive results here #ASCO26

Interested in the assumptions/stats behind the planned phase 3 trial. Given the effect in the phase 2 seems so profound why does the sample size need to be so big in the phase 3 (n=750)

Are you going for OS?

[Shilpa Gupta @shilpaonc]

Superb presentation by @RWinayak mentee of the amazing @montypal
on microbial dysbiosis as predictor of benefit of microbiome CBM588 when added to ICI in RCC. #ASCO26 @ASCO

Very promising clinical outcomes laying the foundation of the ph 3 BIOFRONT trial led by @PBarataMD @SWOG
Kudos to @montypal for opening the frontier of Microbiome's to enhance ICI efficacy in RCC.

[Matthew Herper @matthewherper]

People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously.

Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here.

This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group.

If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.

[Dr Joseph McCollom DO @realbowtiedoc]

What an interrupting standing #ovation looks like from the front of #ASCO26 when a revolution in science comes for #pancsm treatment #GIonc.

[A/Prof Tim Clay @drtclay]

@NarjustFlorezMD @CharlesJiangMD I have made the point @NarjustFlorezMD as has @charlesjiangmd this study was in China

China only represents a portion of east Asia

[A/Prof Tim Clay @drtclay]

@NarjustFlorezMD #ASCO26

The incidence of SqCC in women in China where this study was conducted is about 10% of that in men

The sex difference in this study is based on the incidence in the community studied

You can only recruit from what is available

https://t.co/QYmG1sLhJh

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[A/Prof Tim Clay @drtclay]

@NarjustFlorezMD @OncoAlert @OncogeneCancer @YoungLungCancer @ASCO @ASCOPres @IASLC @SMMT_TX @women_in_cancer @OncBrothers This is not a study in Eastern Asia generally

It is a study in China specifically and the incidence of SqCC by sex in China is different.

There is not much SqCC from indoor pollution

https://t.co/jYAWD1pAOp

[A/Prof Tim Clay @drtclay]

@NarjustFlorezMD @OncoAlert @OncogeneCancer @YoungLungCancer @ASCO @ASCOPres @IASLC @SMMT_TX @women_in_cancer @OncBrothers https://t.co/liALrHbht0

[Mark Lewis, MD, FASCO @marklewismd]

As many other oncologists will also attest, we were taught this was a dead end

It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted

And yet here we are, with truly meaningful survival curves👇

Inspiration on multiple levels #ASCO26

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

This is a moral issue for the oncology community. Were a drug or supportive care intervention to show OS curves like this, it would be SOC, and covered. For far less than costs of new drugs, our society could provide food for our patients. Perhaps our clinics need to do that.

[A/Prof Tim Clay @drtclay]

@BalazsHalmosMD #ASCO2026

I don’t understand why Chinese studies get selected for major presentation then get degraded in discussion for only being done in China, particularly when global ph 3 are running in confirmation…

Discussion labouring the point is sadly not helpful

@ASCO

[A/Prof Tim Clay @drtclay]

@Alfdoc2 @g_mountzios @FSkoulidis Ophthalmologists love unblinded studies

[Stephen V Liu, MD @StephenVLiu]

Dr. Caicun Zhou at #ASCO26 with results from phase III OptiTROP-Lung05: first-line sacituzumab govitecan (sac-TMT, TROP2 ADC) + pembro vs pembro for PD-L1+ NSCLC (n=413). Sac-TMT superior with PFS NR vs 6.6m (HR 0.38) with benefit across subgroups.

[A/Prof Tim Clay @drtclay]

@lungoncdoc @ASCO We should be calling out the ALKAZAR 1L study

Inferior control arm to best available care. Alectinib can't be justified as just because lorlatinib is not available everywhere.

No reason @nuvalent can't design and fund a first line trial vs lorlatinib

#ASCO26 @ALKpositiveINT

[Dr Riyaz Shah @DrRiyazShah]

It’s astonishing that CROWN 7y update shows mPFS and median time to IC PFS are still NOT REACHED: Surprisingly only 34% needed a DR and 5% TRAE>discontinuation. Current 4th gen trials will be criticised for inadequate control arms. #ASCO26 @ALKpositiveINT @BTOGORG

[Christine Lovly, MD, PhD, FASCO @christine_lovly]

Impressive data on #nextgen #KRAS G12C inhibitor, Elisrasib, at #AACR26. ORR 73.5% with durable responses to >= 3y in treatment naive population! #LCSM @yonsei_u

[Stephen V Liu, MD @StephenVLiu]

Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor.

[Stephen V Liu, MD @StephenVLiu]

#AACR26 Zoldonrasib in previously treated KRAS G12D NSCLC with RR 52%, DCR 93%, time to response 1.4m, mDOR not reached with median follow up of 13.1m, mPFS 11.1m, and 73% of pts with ctDNA clearance. Fantastic presentation, exciting drug for our patients!